| Name | Title | Contact Details |
|---|
Blue Matter Consulting is a management consulting firm dedicated to the life sciences industry, particularly in pharmaceuticals and biotechnology. Founded in 2012, the company has grown from a single office to a global presence with locations in the United States, Europe, and India. The leadership team, including managing partners Ashwin Dandekar, Emily Hua, and George Schmidt, guides the firms strategic growth. The firm offers a wide range of services to help life sciences companies maximize value. These services include new product planning, launch strategy and management, commercial strategy for existing products, market access strategy, corporate strategy, transaction support, and organizational design. Blue Matter also focuses on specific therapeutic areas such as oncology and rare diseases, providing tailored strategies and solutions. With a diverse client base of over 250 companies, including many top global biopharmaceutical firms, Blue Matter Consulting is recognized for its strategic expertise and personalized service in the life sciences sector.
For over 120 years, Parr Instrument Company has been designing, manufacturing, and selling high quality laboratory instruments and apparatus for conducting chemical reactions and tests under heat and pressure and for testing fuels. Parrs extensive product line includes stirred reactors, pressure vessels, and high pressure tubular reactors for the study of catalytic and non-catalytic reactions in batch, continuous-flow, and multiple/parallel operation for the chemical, polymer, biofuels, hydrometallurgical, pharmaceutical, petroleum, and petrochemical industries. Custom designed complex reactor systems, built to the customers specifications and requirements are also provided. Parrs oxygen combustion calorimeters are used for the determination of the heat of combustion in solid, liquid, and refuse-derived fuels for the energy, educational, coal, and fuel testing industries. Parr also offers sample preparation vessels for extraction, digestion, and hydrothermal synthesis, as well as a line of vessels for cell disruption by nitrogen decompression.
ChefStable partners with chefs to design, build and operate restaurants. We invest in chefs we believe in, chefs who have shown a commitment to their craft and whose food reflects their passion and talent. We take care of all of the operational details which allows our partners to focus on whats truly important: food and service.
Custom Goods Logistics is a full-service logistics company based in Carson, California, with over 60 years of experience in the industry. As a nationally-recognized third-party logistics (3PL) provider, the company employs around 600 people and generates annual revenue of $195.9 million. Custom Goods operates a fleet of more than 175 trucks and manages over 7 million square feet of warehouse space across the United States. The company offers a range of logistics solutions, including warehousing, transportation, specialty freight forwarding, and centralized exam stations. Custom Goods specializes in omni-channel fulfillment, integrating e-commerce, retail, and wholesale operations with advanced inventory management. They serve various sectors, including food and beverage, retail, automotive, industrials, e-commerce, and manufacturing, providing tailored solutions to meet specific client needs. The company emphasizes data-driven decision-making, personalized customer service, and timely solutions, positioning itself as a partner dedicated to supporting business success.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.